GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
AstraZeneca
Washington University School of Medicine
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
City of Hope Medical Center
University of Washington
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Ruijin Hospital
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
Janssen Research & Development, LLC
Ruijin Hospital
PrECOG, LLC.
University of Miami
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Weill Medical College of Cornell University
Sun Yat-sen University
M.D. Anderson Cancer Center
University College, London
University College, London
Eastern Cooperative Oncology Group
Sun Yat-sen University
Academic and Community Cancer Research United
Weill Medical College of Cornell University
Medical University of Vienna
Academic and Community Cancer Research United
City of Hope Medical Center
University of Nebraska
Ruijin Hospital
University of Nebraska
University of Nebraska
University of Nebraska
City of Hope Medical Center
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
The First Affiliated Hospital of Soochow University
Fondazione Italiana Linfomi - ETS
SWOG Cancer Research Network
SWOG Cancer Research Network
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins